Fig. 7

3D U-iKOs disease models. A Immunofluorescence analysis of 3D U-iKOs treated with cisplatin (5 μM) for 24 h. Scale bars, 50 μm. B H and E staining of U-iKOs treated with cisplatin in A. Scale bars, 100 μm. C Scatterplot showing the up-regulated genes (red) and down-regulated genes (blue) between control and cisplatin treatment groups. D GO analysis of C. E Representative bright-field images of control and gentamicin treatment cells. Scale bars, 250 μm. F Immunofluorescence analysis of 3D U-iKOs treated with control and gentamicin (5 mg/mL) for 24 h. G Scatterplot showing the up-regulated genes (red) and down-regulated genes (blue) between control and gentamicin treatment groups. H GO analysis of G. I Heatmap shows common differentially expressed genes of FSK, cisplatin, and gentamicin treatment groups compared to control and their respective differentially expressed genes. J–L Gene expression analysis for differentially expressed genes after cisplatin, gentamicin, and FSK treatment in I. The relative expression of each transcript to GAPDH expression is presented as the mean ± SEM (n = 4). *P < 0.05 vs. the control group; **P < 0.01 vs. the control group; ****P < 0.0001 vs. the control group